Sana Biotech­nol­o­gy snags Os­cine, adding cell ther­a­py leader Steve Gold­man to its star-stud­ded staff

Sana Biotech­nol­o­gy CEO Steve Harr be­gan kick­ing around the idea of ac­quir­ing Os­cine ear­ly on in the com­pa­nies’ part­ner­ship. About a year ago, over din­ner with the Uni­ver­si­ty of Rochester Med­ical Cen­ter spin­out’s CEO and sci­en­tif­ic founder, he pulled the trig­ger.

The part­ners re­al­ized it was “the right thing to do. (And) then it usu­al­ly takes a lot longer than you hope… to get things done,” Harr said. On Fri­day, the com­pa­nies an­nounced they got it done.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.